Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com


LAUSANNE, Switzerland, November 22, 2017 /PRNewswire/ --

Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website patients.debiopharm.com. The website provides patients and their caregivers with helpful information on Debiopharm's clinical trials and studies. It also offers accessible information about the clinical trial process in general.

     (Photo: http://mma.prnewswire.com/media/608971/Debiopharm_International_Website.jpg )

Debiopharm's main therapeutic areas are oncology and infectious diseases. The company is currently conducting trials in multiple indications like Ovarian cancer, Head & Neck cancer and Non-Hodgkin Lymphoma. Additional studies are running in patients with Advanced Solid Malignancies as well. The website contains useful information for each clinical trial such as a short description of the trial process and its purpose, main inclusion criteria, as well as a map locating the study sites (in accordance with the information contained in the EU Clinical Trials Register and the clinicaltrials.gov website). The patient can print the information to discuss with his/her doctor.

"This website is intended to be a helpful tool for patients and their families", explains Christian Aeschlimann, Director of Clinical Operations at Debiopharm International SA. "They can find accessible information related to our clinical trials and treatment options. The website also allows users to share links of patient associations".

The website was developed in collaboration with the Superhuit agency in Lausanne. Created with the user experience in mind, the website includes intuitive design features to help patients to navigate easily and find information.

About Debiopharm International SA 

Part of Debiopharm Grouptm - a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

   
Debiopharm International SA Contact
Christelle von Büren
Communication Coordinator
[email protected]
Tel: +41(0)21-321-01-11


SOURCE Debiopharm International SA


These press releases may also interest you

at 14:50
American Skin Association (ASA) is thrilled to announce that it has received Candid's eminent 2024 Platinum Seal of Transparency and the coveted Four-Star Rating from Charity Navigator. Candid (formerly Guidestar & Foundation Center) is the world's...

at 14:48
Loyal, the San Francisco-based company dedicated to improving the health and longevity of dogs, and Prelude, the leading animal health-focused electronic data capture (EDC) system for clinical research, are proud to announce their strategic...

at 14:45
The federal government recently delivered Budget 2024: Fairness for Every Generation.  It is a plan to build a Canada that works better for everyone, where younger generations can get ahead, where their hard work pays off, and where they can buy a...

at 14:21
The Rideau Hall Foundation (RHF) is delighted to welcome to its board of directors three new members who will help shape the direction and increase the nation-building impact of the RHF's work:...

at 14:16
Gen Z and millennials are the engine of our economy. Everything that is created, built, served, and sold in Canada is increasingly being done by millennials and Gen Z. They're the young parents, the students doing cutting-edge research, the young...

at 14:16
Mednet, a healthcare technology company, today announced Senior Project Manager Stacey Lasser will present at the 2nd Annual Clinical Outsourcing Group (COG) New England conference in Boston, Massachusetts from April 23 ? 24, 2024. Additionally,...



News published on and distributed by: